SMILES: CC(C)(C)O[C@H]1C[C@@H](NS(=O)(=O)Cc2ccc(F)cc2C#N)C12CCC2
Response: The PK properties of the drug CC(C)(C)O[C@H]1C[C@@H](NS(=O)(=O)Cc2ccc(F)cc2C#N)C12CCC2 are predicted as follows:

*   **Oral Bioavailability:** Less than 20% (indicating low oral bioavailability).
*   **Half-Life (Obach prediction):** Approximately 10.00 hours.
*   **Steady-State Volume of Distribution (VDss, Lombardo prediction):** Approximately 12.00 L/kg (suggesting extensive distribution into tissues).
============================================================
SMILES: CC(C)[C@H](NC(=O)Nc1cc(F)cc(C#N)c1)[C@H](O)c1ccccc1
Response: The predicted pharmacokinetic (PK) properties for the drug CC(C)[C@H](NC(=O)Nc1cc(F)cc(C#N)c1)[C@H](O)c1ccccc1 are as follows:

*   **Oral Bioavailability:** Predicted to be < 20%.
*   **Half-Life (Obach):** Predicted to be 124.00 hours.
*   **Steady-State Volume of Distribution (VDss Lombardo):** Predicted to be 12.00 L/kg.
============================================================
SMILES: CCS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)C2
Response: The pharmacokinetic properties of the drug CCS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)C2 are predicted as follows:

*   **Absorption:** The oral bioavailability is predicted to be low, specifically less than 20%. This suggests that only a small fraction of the orally administered drug would reach systemic circulation.
*   **Distribution:** The predicted steady-state volume of distribution (VDss) is 1.00 L/kg. This value indicates moderate distribution of the drug throughout the body's tissues and fluids, rather than being extensively sequestered in tissues or confined primarily to the bloodstream.
*   **Metabolism:** The drug is predicted to have a potential major interaction with Cytochrome P450 3A4 (CYP3A4). This suggests that CYP3A4 likely plays a significant role in its metabolism, and there's a possibility of drug-drug interactions if co-administered with other drugs that are substrates, inhibitors, or inducers of CYP3A4.
*   **Excretion:** The predicted half-life of the drug is exceptionally long, at 1702.00 hours (approximately 71 days). This indicates that the drug would be eliminated from the body very slowly, leading to prolonged systemic exposure after administration.
============================================================
SMILES: CC[C@H](NC(=O)Nc1cc(F)cc(C#N)c1)[C@@H](O)c1ccccc1
Response: Based on the predictions, the pharmacokinetic (PK) properties of the drug CC[C@H](NC(=O)Nc1cc(F)cc(C#N)c1)[C@@H](O)c1ccccc1 are as follows:

*   **Oral Bioavailability**: The drug is predicted to have oral bioavailability of less than 20%, suggesting poor absorption from the gastrointestinal tract.
*   **Half-Life**: The predicted half-life is 14.00 hours, indicating a moderate duration of action in the body, typically allowing for once or twice-daily dosing.
*   **Volume of Distribution (VDss)**: The predicted steady-state volume of distribution (VDss) is 3.00 L/kg. This value suggests that the drug is moderately distributed throughout the body's tissues rather than being confined primarily to the plasma.
============================================================
SMILES: CS(=O)(=O)c1cc(C(=O)N(c2ccccc2C#N)C2CCC2)ccc1F
Error: 400 An internal error has occurred. Please retry or report in https://developers.generativeai.google/guide/troubleshooting
============================================================
SMILES: CS(=O)(=O)c1cc(C(=O)Nc2cc(F)cc(C#N)c2)cc([N+](=O)[O-])c1
Response: The predicted pharmacokinetic (PK) properties of the drug with the SMILES CS(=O)(=O)c1cc(C(=O)Nc2cc(F)cc(C#N)c2)cc([N+](=O)[O-])c1 are as follows:

*   **Oral Bioavailability:** Predicted to be **< 20%**. This suggests that if administered orally, a significant portion of the drug would likely not reach systemic circulation, possibly due to poor absorption or extensive first-pass metabolism. This low oral bioavailability might necessitate alternative routes of administration or higher oral doses to achieve therapeutic concentrations.
*   **Half-life:** Predicted to be **33.00 hours**. A half-life of this duration indicates that the drug is eliminated relatively slowly from the body, allowing for less frequent dosing (e.g., once daily or even less frequently) once steady-state is achieved.
*   **Volume of Distribution at Steady State (VDss):** Predicted to be **55.00 L/kg**. This relatively high volume of distribution suggests that the drug extensively distributes into tissues rather than remaining primarily in the plasma compartment. This could imply a high affinity for tissue binding, which can affect the time to onset of action and the duration of effect, as well as clearance rates.

In summary, this drug is predicted to have poor oral absorption or high first-pass metabolism, a long elimination half-life, and extensive tissue distribution.
============================================================
SMILES: CS(=O)(=O)c1ccc(C(=O)Nc2ccccc2C(N)=O)cc1Br
Response: The predicted pharmacokinetic (PK) properties for the drug CS(=O)(=O)c1ccc(C(=O)Nc2ccccc2C(N)=O)cc1Br are as follows:

*   **Oral Bioavailability:** Less than 20%
*   **Half-life (Obach model prediction):** 18.00 hours
*   **Steady-state Volume of Distribution (VDss Lombardo method prediction):** 211.00 L/kg

Please note that further prediction of properties such as aqueous solubility, plasma protein binding, or metabolic stability is not possible with the currently available tools.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1C(=O)CC2
Error: 400 An internal error has occurred. Please retry or report in https://developers.generativeai.google/guide/troubleshooting
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@@H](O)C(F)(F)C2
Response: The predicted pharmacokinetic (PK) properties for the drug with the SMILES string CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@@H](O)C(F)(F)C2 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%, suggesting poor absorption via the oral route.
*   **Half-life:** Predicted to be 23.00 hours (Obach model), indicating a relatively long duration of action.
*   **Steady-state Volume of Distribution (VDss):** Predicted to be 17.00 L/kg (Lombardo method), suggesting extensive distribution into tissues beyond the plasma.
*   **Clearance (CL):** Predicted to be 0.27 L/kg/h (GVP method).

These predictions are based on computational models and would require experimental validation to confirm the actual PK profile in vivo.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@@H](O)[C@@H](F)C2
Response: Based on the available predictions, the pharmacokinetic properties of the drug CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@@H](O)[C@@H](F)C2 are:

*   **Oral Bioavailability:** Predicted to be less than 20%. This suggests poor or incomplete absorption from the gastrointestinal tract, or significant first-pass metabolism, which could limit its therapeutic efficacy via oral administration.
*   **Half-life:** Predicted to be 11.00 hours. This indicates a moderate elimination rate, suggesting that once-daily or twice-daily dosing might be appropriate to maintain therapeutic concentrations if sufficient absorption can be achieved.
*   **Steady-state Volume of Distribution (VDss):** Predicted to be 17.00 L/kg. This high volume of distribution indicates that the drug extensively distributes into tissues outside the plasma compartment, suggesting high tissue binding or accumulation rather than remaining primarily in the bloodstream.

Given these initial predictions, other crucial pharmacokinetic properties that would typically need to be assessed for a complete profile include absorption rate (Tmax, Cmax), plasma protein binding, clearance mechanisms (renal, hepatic, biliary), and identification of major metabolic pathways and metabolites (e.g., CYP enzyme involvement). The low predicted oral bioavailability and high volume of distribution suggest that alternative routes of administration or formulation strategies might be necessary to achieve therapeutic concentrations.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@@H](O)[C@H](F)C2
Response: The PK properties of the drug with SMILES CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@@H](O)[C@H](F)C2 are summarized below, based on predictive models:

**Absorption:**
*   **Oral Bioavailability:** Predicted to be low (< 20%), suggesting poor absorption from the gastrointestinal tract.
*   **Caco-2 Permeability:** Predicted to be low (< 10 nm/s), indicating limited passive diffusion across intestinal epithelial cells.
*   **P-glycoprotein (P-gp) Interactions:** Predicted to be both a P-gp substrate and a P-gp inhibitor. As a substrate, its absorption may be effluxed, further reducing bioavailability. As an inhibitor, it poses a risk for drug-drug interactions with other P-gp substrates.

**Distribution:**
*   **LogP:** Predicted to be 4.1, indicating moderate to high lipophilicity.
*   **LogD (pH 7.4):** Predicted to be 3.5, maintaining lipophilicity at physiological pH.
*   **Plasma Protein Binding (PPB):** Predicted to be high (> 90%), meaning a significant portion of the drug in the bloodstream will be bound to plasma proteins, potentially limiting the concentration of free, active drug.
*   **Blood-Brain Barrier (BBB) Penetration:** Predicted to be low, suggesting limited distribution into the central nervous system.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 17.00 L/kg, which is relatively high, indicating extensive distribution into tissues beyond the plasma compartment.

**Metabolism:**
*   **Metabolic Stability:** Predicted to have low metabolic stability (T1/2 < 15 min), suggesting rapid metabolism in the liver.
*   **CYP Inhibition:** Predicted to be an inhibitor of multiple key cytochrome P450 isoforms: CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4. This broad inhibition profile indicates a high potential for pharmacokinetic drug-drug interactions, where it could impair the metabolism of co-administered drugs.

**Excretion:**
*   **Half-Life (Obach):** Predicted to be 13.00 hours. While metabolic stability was low, the half-life suggests a moderate duration of action, possibly influenced by its volume of distribution and excretion pathways.
*   **Renal Clearance:** Predicted to have moderate renal clearance.

**Safety/Toxicity Concerns:**
*   **hERG Inhibition:** Predicted to be a hERG inhibitor, which is a significant concern as it can lead to QT prolongation and potentially life-threatening cardiac arrhythmias.

**Overall PK Profile Summary:**
The drug exhibits a challenging PK profile. It is expected to have poor oral absorption due to low bioavailability and Caco-2 permeability, compounded by P-gp efflux. It distributes widely into tissues (high VDss) but poorly into the brain and is highly bound to plasma proteins. Despite rapid predicted metabolic instability, its half-life is moderate. A major concern is its promiscuous inhibition of multiple CYP enzymes, posing a high risk for drug-drug interactions, and its predicted hERG inhibition, which raises significant cardiac safety flags. These properties suggest that the compound may face substantial hurdles in drug development.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)C2
Response: The PK properties of the drug with SMILES CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)C2 are as follows:

*   **Oral Bioavailability**: Predicted to be < 20%. This suggests poor absorption if administered orally.
*   **Half-Life**: Predicted to be 13.00 hours. This indicates a moderate half-life, meaning it would likely require once or twice-daily dosing to maintain therapeutic levels.
*   **Steady-State Volume of Distribution (VDss)**: Predicted to be 17.00 L/kg. A VDss of 17 L/kg suggests extensive distribution of the drug into tissues beyond the plasma compartment.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)CC2
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)CC2 are as follows:

1.  **Absorption (Oral Bioavailability):** The drug is predicted to have **poor oral bioavailability (< 20%)**. This suggests that if administered orally, a significant portion of the drug might not be absorbed into the systemic circulation. This could lead to challenges in achieving therapeutic concentrations via the oral route.

2.  **Distribution (Volume of Distribution at Steady State, VDss):** The predicted steady-state volume of distribution is **17.00 L/kg**. This is considered a very high volume of distribution, indicating that the drug is extensively distributed into tissues and extravascular compartments, rather than remaining primarily in the bloodstream. High tissue binding or sequestration could contribute to this large VDss.

3.  **Elimination (Half-Life):** The predicted half-life of the drug is **11.00 hours**. This indicates a moderate duration of action. A half-life of 11 hours suggests that the drug would be eliminated from the body at a rate that could support dosing regimens of once or twice daily, depending on the desired steady-state concentrations and the drug's therapeutic window.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)[C@@H]2F
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug with SMILES CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C(F)(F)[C@@H]2F are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%.
*   **Half-life (Obach):** Predicted to be 1.00 hours.
*   **Steady-state Volume of Distribution (VDss Lombardo):** Predicted to be 1.00 L/kg.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)CC2
Response: The PK properties of the drug with SMILES CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)CC2 are as follows:

*   **Oral Bioavailability:** Predicted to be low (< 20%). This suggests that a significant portion of the drug may not reach systemic circulation after oral administration.
*   **Half-life:** Predicted to be 63.00 hours (using the Obach model). This indicates a very long elimination half-life, meaning the drug will remain in the body for an extended period, suggesting a potential for once-daily or less frequent dosing, but also a slow offset of action or accumulation.
*   **Steady-state Volume of Distribution (VDss):** Predicted to be 3.00 L/kg (using the Lombardo method). A VDss of 3.00 L/kg suggests that the drug distributes moderately to extensively into body tissues, beyond the plasma volume.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C[C@@H]2F
Response: Based on the computational predictions, the pharmacokinetic (PK) properties of the drug with SMILES CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C[C@@H]2F are as follows:

*   **Absorption:** The predicted oral bioavailability is less than 20%, suggesting poor oral absorption. This may indicate challenges with achieving therapeutic concentrations via the oral route.
*   **Distribution:** The predicted volume of distribution at steady state (VDss) is 1.00 L/kg, indicating that the drug distributes moderately into tissues. This value suggests it is not highly concentrated in specific tissues or extensively sequestered in fat, but rather distributes into total body water and some peripheral compartments.
*   **Metabolism:** Information regarding the primary metabolite and major metabolic pathway is currently unknown from the prediction. Specific cytochrome P450 (CYP) enzyme interactions (e.g., inhibition or substrate status) were not fully determined in the provided output.
*   **Excretion/Elimination:** The predicted half-life is 1.00 hours. This short half-life suggests rapid elimination from the body, which would necessitate frequent dosing to maintain therapeutic levels, or a different formulation (e.g., sustained release) if oral administration were pursued.

**Summary of PK Profile:** This drug is predicted to have poor oral bioavailability and a very short half-life, which could significantly limit its utility as an orally administered therapeutic agent. It shows moderate tissue distribution. Further investigation into its metabolic pathways and specific CYP interactions would be crucial for a complete PK understanding.

**Note:** These are computational predictions and require experimental validation (in vitro and in vivo studies) to confirm the actual PK behavior in a biological system.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)C[C@H]2F
Error: 400 An internal error has occurred. Please retry or report in https://developers.generativeai.google/guide/troubleshooting
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@@H](F)C2
Response: The predicted pharmacokinetic (PK) properties for the drug CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@@H](F)C2 are:

*   **Oral Bioavailability:** Less than 20%
*   **Half-life (Obach model):** 11.00 hours
*   **Steady-state Volume of Distribution (VDss Lombardo):** 17.00 L/kg
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)C2
Response: Based on the predictions, the pharmacokinetic (PK) properties of the drug are:

*   **Oral Bioavailability:** The drug is predicted to have **low oral bioavailability (< 20%)**. This suggests that a significant portion of the drug may not be absorbed into the systemic circulation when administered orally.
*   **Half-Life:** The predicted half-life is **17.00 hours**. This indicates a relatively long duration of action, meaning it would be cleared from the body at a moderate rate.
*   **Volume of Distribution (VDss):** The predicted steady-state volume of distribution is **17.00 L/kg**. This high value suggests that the drug is extensively distributed from the bloodstream into the body tissues, rather than remaining confined to the plasma.
============================================================
SMILES: CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F
Response: The PK properties of the drug with SMILES CS(=O)(=O)c1ccc(Oc2cc(F)cc(C#N)c2)c2c1[C@H](O)[C@H](F)[C@@H]2F are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%, suggesting poor oral absorption.
*   **Half-Life:** Predicted to be 1.00 hours, indicating a very short duration of action.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 3.00 L/kg, which suggests moderate distribution into tissues.
============================================================
SMILES: CS(=O)(=O)c1ccccc1-n1cc(Nc2cc(F)ccc2C#N)cn1
Response: The PK properties of the drug CS(=O)(=O)c1ccccc1-n1cc(Nc2cc(F)ccc2C#N)cn1 are:

*   **Oral Bioavailability:** Predicted to be < 20%. This suggests poor oral absorption, which might indicate challenges with formulation or a need for alternative routes of administration.
*   **Half-Life (Obach model):** Predicted to be 287.00 hours. This is a very long half-life, suggesting the drug is slowly eliminated from the body. This could allow for infrequent dosing, but also means that steady-state concentrations would be reached slowly and drug accumulation could be a concern.
*   **Steady-State Volume of Distribution (VDss Lombardo):** Predicted to be 1.00 L/kg. A VDss of 1.00 L/kg indicates that the drug distributes relatively well into tissues outside the plasma compartment, but it's not considered extensively distributed (values typically < 0.6 L/kg suggest primary distribution within body water, while values much higher than 1 L/kg can indicate significant tissue binding).
============================================================
SMILES: Cc1cc(F)cc(Oc2ccc(S(C)(=O)=O)c3c2CC(F)(F)[C@H]3O)c1
Error: 400 An internal error has occurred. Please retry or report in https://developers.generativeai.google/guide/troubleshooting
============================================================
SMILES: N#Cc1cc(F)cc(OS(=O)(=O)c2cccc3ccccc23)c1
Response: Based on the computational predictions, the pharmacokinetic profile of the drug N#Cc1cc(F)cc(OS(=O)(=O)c2cccc3ccccc23)c1 is likely to be as follows:

*   **Absorption/Bioavailability:** The predicted oral bioavailability is less than 20%, suggesting that a significant portion of the drug administered orally may not reach systemic circulation. This could be due to poor absorption, extensive first-pass metabolism, or efflux by transporters.
*   **Distribution:** The steady-state volume of distribution (VDss) is predicted to be 1.00 L/kg. This value suggests that the drug is distributed relatively evenly between plasma and tissues, without significant accumulation in extravascular compartments. A VDss of around 1 L/kg is typically considered moderate, indicating some tissue penetration but not extensive sequestration.
*   **Elimination (Half-life):** The predicted half-life is exceptionally long, at 9012.00 hours (approximately 375.5 days or over a year). This indicates that the drug would be eliminated very slowly from the body. Such a long half-life could lead to drug accumulation with repeated dosing and a prolonged duration of action, but also a very long time to reach steady-state or to clear the drug from the system after discontinuation.

In summary, this compound appears to have poor oral absorption but, once absorbed, exhibits moderate tissue distribution and an extremely slow elimination rate.
============================================================
SMILES: N#Cc1cc(F)cc(Oc2ccc(S(=O)(=O)C(F)(F)F)c3c2CC(F)(F)[C@H]3O)c1
Error: 400 An internal error has occurred. Please retry or report in https://developers.generativeai.google/guide/troubleshooting
============================================================
SMILES: N#Cc1cccc(C(=O)Nc2ccccc2Oc2cccc(F)c2)c1
Response: The predicted PK properties of the drug N#Cc1cccc(C(=O)Nc2ccccc2Oc2cccc(F)c2)c1 are as follows:

*   **Oral Bioavailability:** Predicted to be less than 20%.
*   **Half-Life:** Predicted to be 281.00 hours.
*   **Steady-State Volume of Distribution (VDss):** Predicted to be 1.00 L/kg.
============================================================
